Physician

Brian F Canavan, DO

According to 2025 Medicare claims, Brian Canavan, DO (NPI: 1760595516) practices hematology/oncology in the Lakewood-New Brunswick, NJ market, with the plurality of this provider's patient population coming from Middlesex, NJ. This provider's primary affiliated billing organization is TITAN HEALTH PARTNERS LLC (NPI: 1790396281; TIN: 852303328) and primary practice location at 08820-1103. Canavan is affiliated with the Physician Leaders Direct Contracting Entity, LLC (ACO ID: D0171) and Vytalize Health 9 ACO LLC (ACO ID: D0313), participating under the REACH model.

Canavan's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 875 traditional Medicare patients, billed 198,678 HCPCS/CPT codes, and received $3,752,730 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 2,362 prescription claims across 392 beneficiaries totaling $6,497,030 in drug costs, led by Neulasta (Pegfilgrastim). DME data shows 55 claims. Open Payments data shows 38 records totaling $680. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have moved from a lower plateau to a higher plateau, from $1,340,237 to $6,497,030. In contrast, DME billing represents a smaller volume and moved from a higher plateau to a lower plateau, from $12,558 to $3,842.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	859	184,494	$2,714,426
2016	960	207,232	$2,901,706
2017	891	214,168	$3,504,699
2018	883	228,542	$3,870,076
2019	867	216,808	$3,569,463
2020	755	167,282	$2,696,276
2021	716	194,239	$3,086,484
2022	775	192,000	$2,536,533
2023	848	211,177	$3,532,219
2024	875	198,678	$3,752,730

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	206	1,208	$1,340,237
2016	230	1,481	$1,944,935
2017	250	1,456	$2,553,866
2018	253	1,706	$4,114,234
2019	273	1,558	$4,302,026
2020	257	1,737	$5,072,072
2021	272	1,606	$4,585,729
2022	302	1,767	$4,422,193
2023	338	2,228	$5,749,615
2024	392	2,362	$6,497,030

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	33	233	$53,350
2016	63	443	$47,919
2017	88	393	$38,508
2018	22	374	$28,843
2019	83	541	$36,214
2020	76	470	$28,634
2021	N/R	308	$13,147
2022	N/R	223	$9,921
2023	N/R	150	$16,301
2024	N/R	55	$3,667

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	505	1,163	$111
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	219	369	$80
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	182	783	$72
36415	Insertion of needle into vein for collection of blood sample	440	1,207	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	335	1,266	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Neulasta	Pegfilgrastim	72	1,729	$588,704
Pomalyst	Pomalidomide	27	756	$579,892
Tagrisso	Osimertinib Mesylate	28	840	$450,897
Revlimid	Lenalidomide	21	574	$381,573
Ojjaara	Momelotinib Dihydrochloride	14	420	$378,306

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
E0781	Ambulatory infusion pump, single or multiple channels, electric or battery operated, with administrative equipment, worn by patient	Y	N/R	12	$2,579
A4222	Infusion supplies for external drug infusion pump, per cassette or bag (list drugs separately)	N	N/R	13	$509
J9190	Injection, fluorouracil, 500 mg	N	N/R	15	$291
A4221	Supplies for maintenance of non-insulin drug infusion catheter, per week (list drugs separately)	N	N/R	15	$288

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	37	$680	PFIZER INC.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	1	$5,000	Cornerstone Specialty Network LLC

Explore More Providers

FAQ

What Medicare data is available for Brian F. Canavan, DO?

Tedicare shows public-source Medicare data for Brian F. Canavan, DO (NPI 1760595516), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Brian F. Canavan, DO have ACO affiliation data?

Brian F. Canavan, DO is shown with ACO affiliation data for Physician Leaders Direct Contracting Entity, LLC (REACH, ACO ID D0171) and Vytalize Health 9 ACO LLC (REACH, ACO ID D0313).

What billing organization is linked to Brian F. Canavan, DO?

Brian F. Canavan, DO is linked to TITAN HEALTH PARTNERS LLC (billing NPI 1790396281) in the available physician profile data.

Does Brian F. Canavan, DO have Open Payments data?

Brian F. Canavan, DO has 38 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.